Latest Government Incentives News

Immutep Limited has received a significant A$4.6 million cash payment from the French government’s R&D tax incentive scheme, supporting its ongoing immunotherapy clinical programs.

Galan Lithium has completed a $20 million placement and secured Argentine government incentives, advancing its Hombre Muerto West lithium project toward first production in early 2026.

Green & Gold Minerals has successfully listed on the ASX, raising $5.7 million to fund drilling at its Chillagoe Gold Project, with initial results expected soon. The company also holds promising critical minerals prospects in Queensland.

Cambium Bio has locked in a significant R&D tax rebate and forged three strategic partnerships, underpinning its Phase 3 clinical trials for its lead ophthalmology biologic. The company’s recent capital raise further strengthens its runway as it prepares for pivotal trial milestones.

Actinogen Medical has received approval for an additional $1.87 million research and development tax rebate, bringing its total FY25 rebate to $7.36 million. This funding underpins ongoing clinical trials of its Alzheimer’s and depression therapy candidate, Xanamem.

Australian Strategic Materials secures A$50.8 million via share placement to fund Korean plant expansion and advance US metals project, while navigating complex supply chain and funding risks.

Connexion Mobility reported a modest 1% revenue increase to $2.9 million in Q1 FY26, while net profit before tax declined 19% due to the absence of prior quarter government incentives. The company is advancing its SaaS platform footprint in US automotive retail and investing strategically in Covertrue Group.

Battery Age Minerals (ASX – BM8) showcased its global portfolio of critical minerals projects at the Ignite Investment Summit in Hong Kong, highlighting maiden drilling at Austria’s Bleiberg germanium project, a newly granted drill permit for Argentina’s El Aguila gold-silver system, and ongoing lithium exploration in Canada’s Falcon Lake.

Actinogen Medical has secured an initial $5.5 million R&D tax incentive rebate from the Australian Tax Office, with an additional $1.9 million pending, bolstering funding for its Alzheimer’s and depression drug trials.

COG Financial Services is raising A$20 million through an institutional placement to acquire an additional 14.08% stake in Fleet Network, increasing its ownership to over 92%. This move is expected to immediately enhance earnings per share and support COG’s strategic growth in novated leasing and salary packaging.

NH3 Clean Energy updates investors on the WAH2 clean ammonia project, highlighting strong market potential, strategic partnerships, and robust project economics as it moves toward a Final Investment Decision.

Opthea Limited has received a substantial A$10.8 million R&D tax incentive from the Australian government, reinforcing its commitment to advancing its novel drug candidate sozinibercept. This funding milestone underscores the company’s strategic focus on innovation and fiscal discipline.